Evidence map›Paper›PMID 34439967›Full record

ArticleBiology2021

Clinical Outcome Prediction in COVID-19 Patients by Lymphocyte Subsets Analysis and Monocytes' iTNF-α Expression.

Gabriele Madonna, Silvia Sale, Mariaelena Capone, Chiara De Falco, Valentina Santocchio, Tiziana Di Matola, Giuseppe Fiorentino, Caterina Pirozzi, Anna D'Antonio, Rocco Sabatino and 17 more

Open access · goldAbstract read
In one paragraph

Article in Biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 5 institutions in 1 country.

Gabriele MadonnaMelanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy.ORCID 0000-0001-9395-3190
Silvia SaleUOC Biochimica Clinica, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
Mariaelena CaponeMelanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy.ORCID 0000-0002-1352-2532
Chiara De FalcoUOC Biochimica Clinica, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.ORCID 0000-0003-2246-6955
Valentina SantocchioUOC Biochimica Clinica, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
Tiziana Di MatolaUOC Biochimica Clinica, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
Giuseppe FiorentinoUOC Fisiopatologia e Riabilitazione Respiratoria, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
Caterina PirozziUOC Biochimica Clinica, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
Anna D'AntonioUOC Biochimica Clinica, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
Rocco SabatinoUOC Biochimica Clinica, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
Lidia AtripaldiDipartimento di Scienze Mediche Traslazionali, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.ORCID 0000-0003-4370-7682
Umberto AtripaldiDipartimento di Scienze Mediche Traslazionali, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
Marcello RaffoneUOC Microbiologia e Virologia, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
Marcello CurviettoMelanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy.
Antonio Maria GrimaldiMelanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy.
Vito VanellaMelanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy.
Lucia FestinoMelanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy.
Luigi ScarpatoMelanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy.
Marco PallaMelanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy.
Michela SpatarellaUOSD di Farmacia, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
Francesco PernaDipartimento di Medicina Clinica e Chirurgia, Università degli Studi di Napoli "Federico II", 80131 Naples, Italy.
Pellegrino CerinoIstituto Zooprofilattico Sperimentale del Mezzogiorno, 80055 Portici, Italy.
Gerardo BottiScientific Direction, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy.
Roberto ParrellaUOC Malattie Infettive ad Indirizzo Respiratorio, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
Vincenzo MontesarchioUOC Oncologia, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
Paolo Antonio AsciertoMelanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy.ORCID 0000-0002-8322-475X
Luigi AtripaldiUOC Biochimica Clinica, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
Ospedale Monaldi · ITIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITUniversity of Campania "Luigi Vanvitelli" · ITIstituto Zooprofilattico Sperimentale del Mezzogiorno · ITUniversity of Naples Federico II · IT

Funding

Regione Campania POR FESR CAMPANIA 2014-2020", CUP H64I20000300002.
6 · The paper itself

Abstract

In December 2019, a novel coronavirus, "SARS-CoV-2", was recognized as the cause of coronavirus disease 2019 (COVID-19). Several studies have explored the changes and the role of inflammatory cells and cytokines in the immunopathogenesis of the disease, but until today, the results have been controversial. Based on these premises, we conducted a retrospective assessment of monocyte intracellular TNF-α expression (iTNF-α) and on the frequencies of lymphocyte sub-populations in twenty-five patients with moderate/severe COVID-19. We found lymphopenia in all COVID-19 infected subjects compared to healthy subjects. On initial observation, in patients with favorable outcomes, we detected a high absolute eosinophil count and a high CD4+/CD8+ T lymphocytes ratio, while in the Exitus Group, we observed high neutrophil and CD8+ T lymphocyte counts. During infection, in patients with favorable outcomes, we observed a rise in the lymphocyte count, in the monocyte and in Treg lymphocyte counts, and in the CD4+ and in CD8+ T lymphocytes count but a reduction in the CD4+/CD8+ T lymphocyte ratio. Instead, in the Exitus Group, we observed a reduction in the Treg lymphocyte counts and a decrease in iTNF-α expression. Our preliminary findings point to a modulation of the different cellular mediators of the immune system, which probably play a key role in the outcomes of COVID-19.

Indexed as

COVID-19eosinophilsiTNF-αlymphocytesmonocytesneutrophilsSARS-CoV-2tregs

Identifiers

PMID34439967
PMCPMC8389652
OpenAlexW3191435490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.